Growing evidence supports that LKB1-deficient KRAS-driven lung tumor represents a unique therapeutic challenge, displaying strong cancer plasticity which promotes lineage conversion and drug resistance. Here we find that murine lung tumors from KrasLSL-G12D/+; Lkb1flox/flox (KL) model show strong pl...
